TickerFacts.

Compare

Acadia Pharmaceuticals Inc vs Madrigal Pharmaceuticals, Inc. vs Ionis Pharmaceuticals Inc vs Indivior Pharmaceuticals, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearAcadia Pharmaceuticals Inc
ACAD		Madrigal Pharmaceuticals, Inc.
MDGL		Ionis Pharmaceuticals Inc
IONS		Indivior Pharmaceuticals, Inc.
INDV
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$1.07B$958.40M$943.71M$1.24B
Revenue growth (YoY)+11.9%+432.1%+33.8%+4.3%
Gross margin91.7% (computed)n/an/a80.2%
Operating margin9.8%-31.3%-40.4%21.1%
Net margin36.5%-30.1%-40.4%16.9%
Net income$391.00M-$288.28M-$381.39M$210.00M
EPS (Diluted)$2.30-$12.85-$2.38$1.64
Operating cash flow$109.84M-$189.55M-$268.58M-$27.00M
Free cash flow$105.15M-$190.02M-$320.03M-$93.00M
Cash & equivalents$177.69M$198.69M$372.26M$195.00M
Total assets$1.56B$1.26B$3.52B$1.20B
Total liabilities$336.81M$656.90M$3.03B$1.30B
Shareholders' equity$1.23B$602.69M$489.09M-$98.00M
Return on year-end equity31.9%-47.8%-78.0%n/a
Shares outstanding170.31M22.84M163.30Mn/a

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearAcadia Pharmaceuticals IncMadrigal Pharmaceuticals, Inc.Ionis Pharmaceuticals IncIndivior Pharmaceuticals, Inc.
Latest$1.07B
Ended 2025-12-31		$958.40M
Ended 2025-12-31		$943.71M
Ended 2025-12-31		$1.24B
Ended 2025-12-31
1 year earlier$957.80M
Ended 2024-12-31		$180.13M
Ended 2024-12-31		$705.14M
Ended 2024-12-31		$1.19B
Ended 2024-12-31
2 years earlier$726.44M
Ended 2023-12-31		$0
Ended 2023-12-31		$787.65M
Ended 2023-12-31		$1.09B
Ended 2023-12-31
3 years earlier$517.24M
Ended 2022-12-31		$0
Ended 2022-12-31		$587.37M
Ended 2022-12-31		$901.00M
Ended 2022-12-31
4 years earlier$484.14M
Ended 2021-12-31		$0
Ended 2021-12-31		$810.46M
Ended 2021-12-31		n/a